Title : One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant.

Pub. Date : 2012 Dec

PMID : 23082898






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVES: The once-daily prolonged-release formulation of tacrolimus (tacrolimus QD) is expected to demonstrate equivalent efficacy and safety to the twice-daily formulation (tacrolimus BID). Tacrolimus BH3 interacting domain death agonist Homo sapiens
2 CONCLUSIONS: Patients taking tacrolimus QD tended to have lower trough levels and require higher dosages than those taking tacrolimus BID during the early posttransplant period, though the differences decreased with increasing time after transplant. Tacrolimus BH3 interacting domain death agonist Homo sapiens